Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca

barbara.lempert NEW YORK, May 28, 2013 /PRNewswire/ — Omthera Pharmaceuticals and AstraZeneca announced today that the companies entered into a merger agreement under which AstraZeneca ...

Feds subpoena Forest Labs in Tudorza Pressair investigation

Tracy Staton In a securities filing, Forest Laboratories disclosed a new subpoena from the feds, requesting documents related to its new lung treatment Tudorza Pressair. FiercePharma ...

FDA Recommends Running Phase 2b Trial of Proellex-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids

barbara.lempert THE WOODLANDS, Texas, May 22, 2013 (GLOBE NEWSWIRE) — Repros Therapeutics Inc.(R) (Nasdaq:RPRX) today announced it has met with the FDA regarding the clinical ...

AstraZeneca bets up to $443M on Omthera lipid drug

Tracy Staton Pipeline-starved AstraZeneca snapped up Omethera. FiercePharma News

Tweets of the Day, 5/28/2013

chris.truelove by Christiane Truelove After a nice holiday weekend with unexpectedly great weather, it’s back to the office and rain today. And yes, back to Twitter and teh Intarwebz. ...

Valeant scoops up Bausch + Lomb as it eyes $20B in revenues

Alok Saboo After rumors of balked-at price tags and an in-the-making IPO, eye-care giant Bausch + Lomb will soon belong to Valeant Pharmaceuticals in exchange for $ 8.7 billion. FiercePharma ...

Addex Announces Steps to Capture Potential Upside from its Partnered Asset and Preserve Value for Shareholders

barbara.lempert Company intends to restructure the organization and monetize its pipeline and platform assets   Geneva, Switzerland, 28 May 2013 – Addex Therapeutics (SIX: ...

Are biotech IPOs already getting too hot to handle?

John Carroll Later this week a pair of biotechs–Cambridge, MA-based Epizyme and Israel's Kamada–are expected to join the lengthening list of drug developers going public ...

When is it fair to slap a ‘pay for delay’ label on a patent settlement?

Tracy Staton Are antitrust regulators unfairly targeting BIg Pharma's patent settlements? As the debate rages on–and continues to spread–more experts and pharma execs ...

Pharmaxis to Cut 30% of Staff

barbara.lempert Pharmaxis Announces Outcome of Business Review Pharmaceutical company Pharmaxis (ASX:PXS) today announced a revised business plan that delivers significant reductions ...

Japanese pharma giants launch $100M global R&D initiative

John Carroll In a sharp reversal of its long neglect of diseases that afflict in the poor in the world's emerging markets, a slate of Japan's top pharma companies have joined ...

Drugmakers to reap $115B in sales as Obamacare rolls on, study finds

Tracy Staton Big Pharma will soon see the payoff from Obamacare. Citing a new GlobalData study, Forbes says the industry stands to reap an additional $ 35 billion in profits as the ...
Page 10 of 34« First...89101112...2030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS